Home
Mabwell Biotech

Mabwell Biotech Market Share Analysis for October 2026

迈威生物是一家全产业链布局的创新型生物制药公司，始终秉承“让创新从梦想变成现实”的愿景，践行“探索生命，惠及健康”的使命，通过源头创新，为患者提供疗效更好、可及性更强的生物创新药，满足全球未被满足的临床需求。

Health > Biotechnology and Pharmaceuticals

Domainmabwell.com

Year Founded2017

Employees1001 - 5000

Annual Revenue$2M - $5M

Mabwell Biotech

Mabwell Biotech (including company regionals)

mabwell.com

See more website traffic and engagement information

Mabwell Biotech Revenue up to October 2026 is 2M - 5M

revenue generated by Mabwell Biotech top domains

Mabwell Biotech top domains revenue over 3 years

Revenue for Mabwell Biotech top domains

mabwell.com2M - 5M

See more with Sales Intelligence

Total visits to Mabwell Biotech's top domains

Understand Mabwell Biotech market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

mabwell.com6.6K

See more with Sales Intelligence

Avg. visit duration in Mabwell Biotech's top domains

Analyze Mabwell Biotech engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

mabwell.com00:03:33

See more with Sales Intelligence

Avg. pageviews on Mabwell Biotech's top domains

See how Mabwell Biotech keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

mabwell.com5.09

See more with Sales Intelligence

Mabwell Biotech top competitors by domain

Top similar sites in October 2026, ranked by their affinity

aditumbio.comCompany NameAditum BioEmployees51 - 200HQUnited States, California, OaklandAnnual revenue--Total visits4.1KN/A

Top technologies used by Mabwell Biotech

These are the website technologies, by industry, used by Mabwell Biotech top domains

Advertising (1)

PubMatic

Conversion & Analytics (1)

CNZZ

Email Services (1)

QQ Mail

Mobile (1)

Meta Viewport

More Technologies

2

See all

News & Signals from Mabwell Biotech

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMabwell plans to present Phase II clinical data at the 2026 European Society for Medical Oncology (ESMO) CongressSHANGHAI, Oct. 18, 2026 /PRNewswire/ - Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821 (Bulumtatug Fuvedotin, "BFv") in locally advanced or metastatic triple-negative breast cancer (TNBC) as an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.

NewsMabwell positions its Nectin-4 ADC as a potential competitor to Pfizer Inc in cervical cancer in Denmark on Jun 19th '26Mabwell's Nectin-4 ADC challenges Pfizer's Tivdak with 77% response rate in combination study.

NewsMabwell presents clinical results at 2026 ESMO Gynaecological Cancers Congress in Denmark on Jun '26Mabwell presents clinical results of nectin-4-targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress.